Literature DB >> 16987903

Histological parameters helpful in recognising steroid-treated temporal arteritis: an analysis of 35 cases.

Ramon L Font1, Venkatesh C Prabhakaran.   

Abstract

AIM: To establish the histological and immunohistochemical parameters that are helpful in recognising temporal arteritis in patients who have been treated with steroids before biopsy, and to analyse the clinical features and correlate them with the histological findings.
METHODS: A retrospective review of charts of 35 patients treated with steroids before obtaining temporal artery biopsy specimens, spanning a 11-year period from 1995 to 2005. The study was conducted at the Ophthalmic Pathology Laboratory, Cullen Eye Institute, Houston, Texas, USA. The clinical features were evaluated and correlated with the histopathological findings. Each case was evaluated with respect to age, sex, race, clinical findings, erythrocyte sedimentation rate, corticosteroid dosage (oral versus intravenous) and the duration of treatment. The time interval between obtaining the biopsy specimen and the onset of steroid treatment was carefully recorded for each patient. In selected cases, histiocytic markers (CD-68 and HAM-56) were used to identify the presence of epithelioid histiocytes, which characterises a granulomatous inflammation. Other immunohistochemical studies (CD3, CD20, CD4, CD8, CD45RO, CD45RA and S-100 protein) were performed in selected cases to characterise the inflammatory cells.
RESULTS: The three most reliable histopathological parameters of corticosteroid-treated temporal arteritis are the following: (1) complete or incomplete mantle of lymphocytes and epithelioid histiocytes located between the outer muscular layer and the adventitia; (2) large circumferential defects in the elastic lamina (best seen with the Movat's pentachrome); and (3) absent or few small multinucleated giant cells. In some cases the main artery appears normal, whereas the primary branches show evidence of a healing arteritis. The histological findings vary according to the duration of treatment before obtaining the biopsy specimen.
CONCLUSION: Striking histological differences can be recognised objectively between patients with active (untreated) giant cell arteritis and patients who have been treated with corticosteroids. The earliest histopathological changes were detected by the end of the first week after steroid treatment (usually after day 4 to the end of the first week). The histological findings were more difficult to recognise at 2-3 months after steroid treatment. Ophthalmic and general pathologists should be able to recognise this entity on the basis of the histological findings including the special stains and results of immunohistochemical studies (CD-68 and HAM-56).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16987903      PMCID: PMC1857614          DOI: 10.1136/bjo.2006.101725

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  23 in total

1.  Use of agar in ophthalmic pathology: a technique to improve the handling and diagnosis of temporal artery biopsies, subfoveal membranes, lens capsules, and other ocular tissues.

Authors:  F J LoRusso; R L Font
Journal:  Ophthalmology       Date:  1999-11       Impact factor: 12.079

Review 2.  Medium- and large-vessel vasculitis.

Authors:  Cornelia M Weyand; Jörg J Goronzy
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

3.  A "negative" temporal artery biopsy, positive for arteritis.

Authors:  Cynthia S Chiu; Thaddeus P Dryja; Simmons Lessell
Journal:  Arch Ophthalmol       Date:  2004-07

4.  Temporal arteritis: improvement in visual prognosis and management with repeat biopsies.

Authors:  D N Cohen
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1973 Jan-Feb

5.  Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings.

Authors:  P Fauchald; O Rygvold; B Oystese
Journal:  Ann Intern Med       Date:  1972-12       Impact factor: 25.391

6.  Manifestations of giant cell arteritis.

Authors:  L A Healey; K R Wilske
Journal:  Med Clin North Am       Date:  1977-03       Impact factor: 5.456

7.  Skip lesions in temporal arteritis.

Authors:  R G Klein; R J Campbell; G G Hunder; J A Carney
Journal:  Mayo Clin Proc       Date:  1976-08       Impact factor: 7.616

8.  The epidemiology of giant cell arteritis : a 12-year retrospective study.

Authors:  N H Liu; L D LaBree; S E Feldon; N A Rao
Journal:  Ophthalmology       Date:  2001-06       Impact factor: 12.079

9.  Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis.

Authors:  N Ray-Chaudhuri; D Ah Kiné; S O Tijani; D V Parums; N Cartlidge; N P Strong; M R Dayan
Journal:  Br J Ophthalmol       Date:  2002-05       Impact factor: 4.638

10.  Temporal arteritis. Comparison of histological and clinical findings.

Authors:  D Schmidt; K U Löffler
Journal:  Acta Ophthalmol (Copenh)       Date:  1994-06
View more
  11 in total

1.  [Bitemporal scalp necrosis : a very rare manifestation of giant cell arteritis].

Authors:  E M Valesky; M Wahle; S Vranes; M Wolter; R Kaufmann; M Meissner
Journal:  Z Rheumatol       Date:  2012-11       Impact factor: 1.372

Review 2.  [Histopathology of systemic vasculitis].

Authors:  K Holl-Ulrich
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011

3.  Clinicopathologic correlations in giant cell arteritis: a retrospective study of 107 cases.

Authors:  Ling Zhou; Katie Luneau; Cornelia M Weyand; Valérie Biousse; Nancy J Newman; Hans E Grossniklaus
Journal:  Ophthalmology       Date:  2009-06-04       Impact factor: 12.079

Review 4.  [Vasculitis: histopathology and differential diagnosis].

Authors:  K Holl-Ulrich; F Noack; A C Feller
Journal:  Z Rheumatol       Date:  2009-06       Impact factor: 1.372

5.  Neuroimaging and other investigations in patients presenting with headache.

Authors:  Callum W Duncan
Journal:  Ann Indian Acad Neurol       Date:  2012-08       Impact factor: 1.383

6.  Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis.

Authors:  José Hernández-Rodríguez; Giuseppe Murgia; Irama Villar; Elías Campo; Sarah L Mackie; Aruna Chakrabarty; Elizabeth M A Hensor; Ann W Morgan; Carme Font; Sergio Prieto-González; Georgina Espígol-Frigolé; Josep M Grau; Maria C Cid
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

7.  The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis.

Authors:  Karin Jakobsson; Lennart Jacobsson; Aladdin J Mohammad; Jan-Åke Nilsson; Kenneth Warrington; Eric L Matteson; Carl Turesson
Journal:  BMC Musculoskelet Disord       Date:  2016-08-24       Impact factor: 2.362

8.  Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients.

Authors:  Joseph J Maleszewski; Brian R Younge; John T Fritzlen; Gene G Hunder; Jorg J Goronzy; Kenneth J Warrington; Cornelia M Weyand
Journal:  Mod Pathol       Date:  2017-03-03       Impact factor: 7.842

9.  Neural network and logistic regression diagnostic prediction models for giant cell arteritis: development and validation.

Authors:  Edsel B Ing; Neil R Miller; Angeline Nguyen; Wanhua Su; Lulu L C D Bursztyn; Meredith Poole; Vinay Kansal; Andrew Toren; Dana Albreki; Jack G Mouhanna; Alla Muladzanov; Mikaël Bernier; Mark Gans; Dongho Lee; Colten Wendel; Claire Sheldon; Marc Shields; Lorne Bellan; Matthew Lee-Wing; Yasaman Mohadjer; Navdeep Nijhawan; Felix Tyndel; Arun N E Sundaram; Martin W Ten Hove; John J Chen; Amadeo R Rodriguez; Angela Hu; Nader Khalidi; Royce Ing; Samuel W K Wong; Nurhan Torun
Journal:  Clin Ophthalmol       Date:  2019-02-21

10.  Chronic periaortitis (retroperitoneal fibrosis) concurrent with giant cell arteritis: a case report.

Authors:  Ioannis Protopsaltis; Athanasios Sotiropoulos; Argyrios Foteinos; Kassiani Manoloudaki; Kiriaki Boki; Garifallia Linardaki; Athanasia Papazafiropoulou; Stavros Antonopoulos
Journal:  J Med Case Rep       Date:  2014-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.